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INTRODUCTION
Stromal invasion and metastasis are critical prog-
nostic factors in breast cancer. Invasive ductal car-
cinoma of the breast often demonstrates invasive
feature with marked desmoplasia, a so-called “scir-
rhous” type. The molecular mechanism of the des-
moplastic reaction has not yet been fully clarified.
On the other hand, axillary lymph node metastasis
is also common in invasive ductal carcinoma of the
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breast. The decision to perform extended dissection
of residual lymph nodes is based on microscopic
findings on sentinel lymph nodes, but the microenvi-
ronmental mechanism(s) involved in axillary lymph
node metastasis remains obscure. At present re-
garding lymph node metastasis, there seem to be
few useful predictive biomarkers using histology
and immunohistochemistry of primary tumors.
Thrombospondin-1 (TSP-1), an extracellular ma-
trix glycoprotein (1), was initially recognized as an
anti-angiogenic factor (2, 3). TSP-1 inhibits tumor
growth by inhibiting endothelial migration and pro-
liferation via the induction of apoptosis (4) and re-
sults from clinical trials suggested TSP-1 as a po-
tential therapeutic candidate in several cancers (5-
7). However, TSP-1 induced pro-angiogenic activity
in breast cancer cell cultures (8) and several studies
demonstrated that TSP-1 promotes invasion and
metastasis in other cancers (9-11). These findings
indicate that TSP-1 has diverse and complex func-
tions with respect to cancer invasion and metastasis.
It is not yet known if in invasive ductal carcino-
mas with much desmoplasia TSP-1 affects the stro-
mal microenvironment with respect to invasion. To
our knowledge, no studies on the relationship be-
tween TSP-1 expression and the histological struc-
tural pattern of invasive ductal carcinoma of the
breast have been reported. We studied the expres-
sion of TSP-1 by, and the microscopic structural
pattern of, invasive ductal carcinoma to assess
whether TSP-1 participates in the stromal reaction
and invasion of these tumors. We also investigated
the role of TSP-1 by examing metastatic axillary
lymph nodes using surgical specimens from patients
with invasive ductal carcinoma of the breast.
MATERIALS AND METHODS
Case selection and histological categorization
We obtained 101 surgical tissue samples from
101 women (age range 39-92 years) who under-
went resection for invasive ductal carcinoma of the
breast and axillary lymph nodes at Hyogo Prefec-
tural Awaji Hospital, Sumoto City, Japan between
2005 and 2011. Permission for scientific research
using resected tissue was given under a compre-
hensive agreement with ethical regulation in Hyogo
Prefectural Awaji Hospital. None had received
radio- or chemotherapy prior to surgery and all
underwent mastectomy or tumor excision and ax-
illary lymph node dissection. None had undergone
preoperative sentinel lymph node biopsy. Resected
tissues were fixed in 10% neutral formalin. Samples
from tumors and lymph nodes were cut at their
maximum diameter, fixed in 10% neutral forma-
lin, embedded in paraffin, and mounted on glass
slides.
Slides were stained with hematoxylin and eosin
for histological diagnosis. We distinguished two cate-
gories of microscopic structural pattern ; tumors
with a desmoplastic (tumor cell nest surrounded
by thick collagenous fibers) component and tumors
with a non- or minimally (less than 20%) desmoplas-
tic component. To avoid accounting for equivocal
immunoreactivity or false-positivity, a cut-off value
of 20% was applied by modifying the HER2 testing
guideline (12) for TSP-1 positivity.
Immunohistochemistry
For immunohistochemical studies we used 3
micrometer-thick unstained tissue samples mounted
on silane-coated slides (PLC-15, Matsunami, Tokyo,
Japan). Antigen retrieval for TSP-1 was in neutral
citrate buffer using an autoclave (115, 2 min).
Immunoreaction was performed in an Autostainer
system (UNIVERSAL STAINING SYSTEM, Dako,
CA, USA) apparatus. Internal peroxidase was
blocked with Dako REAL Peroxidase (Dako) for 5
min at room temperature. An antibody to TSP-1
(Novocastra, Newcastle, UK ; diluted 1 : 100) was
applied for 30 min at room temperature ; the reac-
tion was completed using the DakoChemMate
ENVISION kit/HRP (DAB) (Dako). Diamino-
benzidine was the chromogen. Cases were consid-
ered to be TSP-1-positive when at least 20% of the
tumor cells expressed TSP-1 in their cytoplasm.
Statistical analysis
Statistical analyses were carried out with the Chi
square test using Statcel 3 software (The Publisher
OMS Ltd., Tokorozawa, Japan). Differences of p
0.05 were considered to be statistically significant.
RESULTS
Microscopic structural pattern and thrombospondin-
1 expression
All 101 tumors manifested the typical histology
of invasive ductal carcinoma with a definite stro-
mal invasion. As shown in Table 1, 69 (68.3%)
were carcinomas with a desmoplastic component
and 32 (31.7%) were non- or minimal desmoplastic.
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Immunoreactivity for TSP-1 was detected in the
cytoplasm of cells from primary tumors and me-
tastatic foci in the lymph nodes (Figures 1 and 2).
In primary tumors, the percentage of TSP-1 im-
munoreactive cells varied from case to case among
the 101 cases ; in 54 cases, at least 20% of the tu-
mor cells were TSP-1-positive. Histologically, 46
of the 54 (85.2%) TSP -1 - positive tumors had a
desmoplastic component (Table 1), and of the 47
TSP-1-negative tumors, 23(48.9%) manifested a des-
moplastic component.
Among the 69 tumors with desmoplastic compo-
nents, 46 (66.7%) were TSP-1-positive while of 32
tumors without- or minimally desmoplastic com-
ponents, 8 (25.0%) were positive for TSP-1. These
findings indicate that the incidence of TSP-1 ex-
pression was significantly higher in tumors with a
desmoplastic component (p0.001, Table 1).
Axillary lymph node metastasis and thrombospondin-
1 expression
Axillary lymph node metastasis from primary
breast carcinoma was found in 39 of the 101 patients
(38.6%) (Figure 2). Among the 54 patients with TSP-
1-positive primary tumors, 28 (51.9%) manifested
axillary lymph node metastasis (Table 2). On the
other hand, 11 of 47 (23.4%) patients with TSP-1-
negative primary tumors had axillary lymph node
A B
Figure 2. (A) Metastatic invasive ductal carcinoma in axillary
lymph nodes. (B) Tumor cells in lymph nodes also showed TSP-
1 expression at a high rate.
A B
C D
Figure 1. Invasive ductal carcinoma of the breast with a des-
moplastic reaction (A) and with a non- or minimally desmoplastic
component (B). Carcinomas with a desmoplastic component (C)
showed TSP-1 immunoreactivity significantly higher than carci-
nomas with a non- or minimally desmoplastic component (D).
Table 1. Microscopic structural pattern and thrombospondin-1 (TSP-1) expression in invasive ductal carcinoma of the breast (n=101)
TSP-1 expression Tumor with a non- or minimally desmoplastic componentn (%)
Tumor with a desmoplastic component
n (%)
Negative (n=47) 24 (75.0) 23 (33.3)
Positive (n=54) 8 (25.0) 46 (66.7)*
Total (n=101) 32 69
*p0.001 vs. Tumor with a non- or a minimally desmoplastic component by Chi square test
Table 2. Axillary lymph node metastasis and thrombospondin-1 (TSP-1) expression in invasive ductal carcinoma of the breast (n=101)
TSP-1 expression Tumor without axillary lymph node metastasisn (%)
Tumor with axillary lymph node metastasis
n (%)
Negative in primary tumor (n=47) 36 (58.7) 11 (26.3)
Negative in axillary lymph nodes 5
Positive in axillary lymph nodes 6
Positive in primary tumor (n=54) 26 (41.3) 28 (73.7)*
Negative in axillary lymph nodes 8 (28.6)
Positive in axillary lymph nodes 20 (71.4)
Total (n=101) 62 39
*p0.005 vs. Tumor without axillary lymph node metastasis by Chi square test
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metastasis. These findings indicate that in patients
with TSP-1-positive primary breast tumors, the in-
cidence of lymph node metastasis was significantly
higher (p0.005, Table 2) than in patients with TSP-
1-negative primary tumors. TSP-1-positive cells
were also present in the lymph nodes with a high
rate of 20 of the 28 cases (71.4%) with TSP-1 posi-
tivity in primary tumors (Figure 2 and Table 2).
Tumor size and thrombopondin-1 expression
According to the TNM classification (13), primary
tumors ranged 43 of T1 (2 cm), 53 of T2 (2 to 5
cm) and 5 of T3 (5 cm) in size. TSP-1 expression
was observed in 19/43 of T1, 32/53 of T2 and 3/5
of T3 tumors. There was no significant difference
in TSP-1 expression between any categories (T1
vs. T2, p=0.169 ; T1 vs. T3, p=0.843 ; T2 vs. T3, p=
0.644)
DISCUSSION
Our immunohistochemical investigation of inva-
sive ductal carcinomas showed that approximately
half of these tumors expressed TSP-1 in the cyto-
plasm. The expression of TSP-1, a modulator of
cell-matrix interactions whose molecular mecha-
nisms play a role in the disease microenvironment,
is usually detected in endothelial cells, platelets, fi-
broblasts, and macrophages in non-neoplastic tissue
(14-18). TSP-1 induces cellular adhesion and mo-
tility, matrix metalloproteinase -2 activation, and en-
dothelial cell apoptosis in inflammation and wound
healing (15, 19-21). In early reports, invasive ductal
carcinomas expressed TSP-1 protein in various lo-
cations such as basement membrane of ducts, stro-
mal tissue and cytoplasm of tumor cells (22-24).
Our findings in the present study indicate that TSP-
1 is primarily produced and regulated by tumor
cells rather than stroma. This suggests that tumor
cells produce TSP-1 to remodel tissue as a better
environment for invasion.
There has been no consensus with respect to the
role of TSP-1 in tumor invasion and metastasis. Cell
culture experiments suggested that the presence of
TSP-1 accelerates invasion and metastasis in many
types of cancer (24-27). On the other hand, Iddings
et al. (27, 28), who studied human colorectal can-
cers immunohistochemically, found that significantly
more tumors without than with lymph node metas-
tasis expressed TSP-1, suggesting that TSP-1 in-
hibits tumor metastasis. In surgical samples from
31 patients with invasive ductal carcinoma of the
breast, Wang-Rodriguez et al. (29) found no sig-
nificant correlation between TSP-1 and lymph node
metastasis. In their study, cases were relatively lim-
ited (twenty-two primary tumors with metastasis
and nine without metastasis), and histological cate-
gorization including desmoplasia was not described.
However, in the present study we had quite a large
number of cases, 101 tumors. We focused on the
desmoplastic reaction and TSP-1 expression and
found that the incidence of lymph node metastasis
was significantly higher in invasive ductal carcino-
mas expressing TSP-1 and that axillary lymph nodes
involving metastasis tended to express TSP-1. Based
on these observations we suggest that TSP-1 ex-
pression by primary breast tumors may be sugges-
tive of their metastatic potential.
Histology of invasive ductal carcinoma of the
breast varies. Desmoplastic carcinomas tend to be
highly invasive (30). In our desmoplastic carcino-
mas, TSP-1 expression was primarily detected in the
tumor cells immunohistochemically, and the des-
moplastic components expressed TSP-1 strongly.
In fact, 2/3 (66.7%) of the tumors with desmoplastic
components expressed TSP-1 and the difference be-
tween desmoplastic- and non- or minimally desmo-
plastic tumors was significant (p0.001). Our re-
sults suggest that TSP-1 released from carcinoma
cells plays a role in the manifestation of the char-
acteristic desmoplastic (scirrhous) features and stro-
mal invasion of breast carcinoma.
Desmoplasia is also recognized in other carcino-
mas. Diffuse-type gastric carcinoma shows similar
histological features to desmoplastic breast carci-
noma. Several reports suggested that expression of
transforming growth factor (TGF)-β and TSP-1 is
closely associated with formation of fibrosis in dif-
fuse-type gastric carcinoma (31-33). TGF-β causes
desmoplasia by induction of myofibroblasts (34, 35).
It is not clear whether gastric and breast carcino-
mas share the same mechanism of desmoplastic
formation. Interaction of TGF-β with TSP-1 should
be investigated in vitro and in vivo in future re-
search.
Our study showed that the incidence of TSP-1
expression was significantly higher in invasive duc-
tal carcinomas of the breast with axillary lymph node
metastasis and in carcinomas with strong desmo-
plastic components. Our results suggest that TSP-
1 plays a role in the invasion and metastasis of these
tumors. Although TSP-1 has been documented to
be anti-angiogenic and suggested as a candidate
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anti-cancer drug, in patients with invasive ductal car-
cinoma of the breast it may promote tumor inva-
sion and is associated with lymph node metastasis.
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